Intra-Cellular Therapies to Host First Quarter 2015 Financial Results Conference Call and Webcast
GlobeNewswire - Fri Apr 24, 7:00AM CDT
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:00 a.m. Eastern Time on Thursday, April 30, 2015, to discuss financial results for the first quarter ended March 31, 2015, and provide a business update.
ITCI: 22.71 (-1.26)
Is Intra-Cellular Therapies (ITCI) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 02, 7:53AM CDT
Intra-Cellular Therapies is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
ITCI: 22.71 (-1.26)
Intra-Cellular Therapies Presents the ITI-007 Clinical Development Program at the 15th International Congress on Schizophrenia Research
GlobeNewswire - Tue Mar 31, 7:00AM CDT
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, presented data regarding the ITI-007 development program and described the rationale supporting the strategy for the advancement of ITI-007 in multiple clinical indications at the 15th International Congress on Schizophrenia Research (ICOSR) in Colorado Springs.
ITCI: 22.71 (-1.26)
Intra-Cellular Therapies to Present at the 15th International Congress on Schizophrenia Research
GlobeNewswire - Wed Mar 25, 7:00AM CDT
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it is scheduled to make presentations regarding its ITI-007 schizophrenia program at the 15th International Congress on Schizophrenia Research (ICOSR) in Colorado Springs, March 28th - April 1st 2015.
ITCI: 22.71 (-1.26)
Intra-Cellular Therapies concludes USD130m in public offering
M2 - Thu Mar 12, 6:52AM CDT
Biopharmaceutical company